Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

DEADLINE NEXT TUESDAY: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

Newsfile June 9, 2022

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 9, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 9, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

PR Newswire June 8, 2022

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 14, 2022 - AUPH

Newsfile June 8, 2022

TUESDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 8, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)

PR Newswire June 8, 2022

7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 7, 2022

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Shareholders

PR Newswire June 7, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

Newsfile June 6, 2022

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 6, 2022

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 3, 2022

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Business Wire June 3, 2022

AUPH SHAREHOLDER ALERT: Jakubowitz Law Reminds Aurinia Pharmaceuticals Inc. Shareholders of a Lead Plaintiff Deadline of June 14, 2022

PR Newswire June 3, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 2, 2022

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 1, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)

PR Newswire June 1, 2022

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Shareholders

PR Newswire May 31, 2022

ROSEN, A LEADING AND RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

PR Newswire May 31, 2022

Aurinia Pharmaceuticals Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 14, 2022 to Discuss Your Rights - AUPH

Newsfile May 30, 2022